A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)

Completed · Phase 3 · Has a placebo group

Conditions studied: Multiple Myeloma

In brief

The purpose of this study is to determine the effect of ixazomib maintenance therapy on progression free survival (PFS) compared with placebo, in participants with NDMM who have had a major response (complete response \[CR\], very good partial response \[VGPR\], or partial response \[PR\]) to initial therapy and who have not undergone SCT.

Key facts

Study ID: NCT02312258
Run by: Takeda
People needed: 706
Starts: 2015-04-09
Expected to finish: 2022-08-26
Last updated by the study team: 2023-09-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Adult male or female participants 18 years or older with a confirmed diagnosis of symptomatic newly diagnosed multiple myeloma (NDMM) according to standard criteria.
Completed 6 to 12 months (± 2 weeks) of initial therapy, during which the participant was treated to best response, defined as the best response maintained for 2 cycles after the M-protein nadir is reached.
Documented major response (PR, VGPR, CR) according to the International Myeloma Working Group (IMWG) uniform response criteria, version 2011, after this initial therapy.
Female participants who:
Are postmenopausal for at least 1 year before the screening visit, OR
Are surgically sterile, OR
If they are of childbearing potential, agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent through 90 days after the last dose of study drug, OR
Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the participant. (Periodic abstinence [eg, calendar, ovulation, symptothermal, postovulation methods] and withdrawal are not acceptable methods of contraception.)
Male participants, even if surgically sterilized (that is, status postvasectomy), who:
Agree to practice effective barrier contraception during the entire study Treatment period and through 90 days after the last dose of study drug, OR
Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the participant. (Periodic abstinence [example, calendar, ovulation, symptothermal, postovulation methods for the female partner] and withdrawal are not acceptable methods of contraception.)
Voluntary written consent must be given before performance of any study-related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the participant at any time without prejudice to future medical care.
Complete documentation of the details of the initial therapy before randomization including cytogenetics and International Staging System (ISS) is available.
Eastern Cooperative Oncology Group Performance Status of 0 to 2.
Suitable venous access for the study-required blood sampling and consent for the specific amounts that will be taken.
Is willing and able to adhere to the study visit schedule and other protocol requirements including blood sampling and bone marrow aspiration.
Must meet the following clinical laboratory criteria at study entry:
Absolute neutrophil count (ANC) greater than or equal to (≥) 1,000 per cubic millimeter (/mm\^3) without growth factor support and platelet count ≥75,000/mm\^3. Platelet transfusions to help participants meet eligibility criteria are not allowed within 3 days before randomization.
Total bilirubin less than or equal to (≤) 1.5*the upper limit of the normal range (ULN).
Alanine aminotransferase and aspartate aminotransferase ≤ 3*ULN.
Calculated creatinine clearance ≥ 30 milliliter per minute (mL/min) (using the Cockcroft-Gault equation).

You may not qualify if…

Multiple myeloma that has relapsed after, or was not responsive to, initial therapy.
Prior SCT.
Radiotherapy within 14 days before randomization.
Diagnosed or treated for another malignancy within 5 years before randomization or previous diagnosis with another malignancy. Participants with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection.
Female participants who are lactating and breastfeeding or have a positive serum pregnancy test during the Screening period.
Major surgery within 14 days before randomization.
Central nervous system involvement.
Infection requiring intravenous (IV) antibiotic therapy or other serious infection within 14 days before randomization.
Diagnosis of Waldenstrom's macroglobulinemia, polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes syndrome (POEMS), plasma cell leukemia, primary amyloidosis, myelodysplastic syndrome, or myeloproliferative syndrome.
Evidence of current uncontrolled cardiovascular conditions, including uncontrolled hypertension, uncontrolled cardiac arrhythmias, uncontrolled congestive heart failure, unstable angina, or myocardial infarction within the past 6 months.
Systemic treatment with strong cytochrome P450 3A (CYP3A) inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital) or St. John's wort within 14 days before randomization.
Ongoing or active infection, known human immunodeficiency virus (HIV) positive, active hepatitis B or C infection.
Comorbid systemic illnesses or other severe concurrent disease that, in the judgment of the investigator, would make the participant inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens (example, PN that is Grade 1 with pain or Grade 2 or higher of any cause).
Psychiatric illness or social situation that would limit compliance with study requirements.
Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent.
Inability to swallow oral medication, inability or unwillingness to comply with the drug administration requirements, or gastrointestinal (GI) procedure that could interfere with the oral absorption or tolerance of treatment.
Treatment with any investigational products within 30 days before randomization.

Where it is running

UCLA Medical Hematology and Oncology — Los Angeles, California, United States
North County Oncology Medical Clinic Inc — Oceanside, California, United States
Ventura County Hematology Oncology Specialists — Oxnard, California, United States
Emad Ibrahim, MD, Inc — Redlands, California, United States
Global Cancer Research Institute (GCRI), Inc. — San Jose, California, United States
Central Coast Medical Oncology Corporation — Santa Maria, California, United States
Winship Cancer Institute, Emory University — Atlanta, Georgia, United States
John H. Stroger Jr. Hospital of Cook County — Chicago, Illinois, United States
Siouxland Hematology - Oncology Associates LLP — Sioux City, Iowa, United States
Appalachian Regional Healthcare — Hazard, Kentucky, United States
New England Cancer Specialists — Scarborough, Maine, United States
Saint Agnes Hospital - Baltimore - Hunt - PPDS — Baltimore, Maryland, United States
University Hospital of Wales - — Bethesda, Maryland, United States
Tufts Medical Center - PPDS — Boston, Massachusetts, United States
Herbert-Herman Cancer Center — Lansing, Michigan, United States
Clinical Research Alliance Inc — New York, New York, United States
New York Presbyterian Hospital - Weill-Cornell — New York, New York, United States
Cancer Care of WNC PA — Asheville, North Carolina, United States
UPMC Cancer Pavillion — Pittsburgh, Pennsylvania, United States
HOPE Cancer Center of East Texas — Tyler, Texas, United States
Swedish Cancer Institute — Seattle, Washington, United States
W VA University Mary Babb Randolph Cancer Center — Morgantown, West Virginia, United States
Hospital Universitario Austral — Buenos Aires, Ciudad Autonoma de BuenosAires, Argentina
Hospital Italiano de Buenos Aires — Buenos Aires, Ciudad Autonoma de BuenosAires, Argentina
Robert A Moss MD FACP Inc — Fountain Valley, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.